NCT07702929Enrolling by invitation
Effect of Hand Rehabilitation on Cognitive Function in Patients With PD
Effect of Sensory-motor Rehabilitation of the Hand on Cognitive Functions in Patients With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Evidence suggests the association between fine motor skills of the hand and cognitive function, as well as the positive effects of hand rehabilitation on hand function and the effectiveness of cognitive rehabilitation on cognitive functions in patients with Parkinson's disease (PD). In response to the question of whether there is a cause-and-effect relationship between fine manual skills and cognitive function, we designed the present randomized controlled trial to investigate the effectiveness of sensory-motor rehabilitation of the hand on cognitive functions compared to the effectiveness of cognitive rehabilitation on sensory-motor skills of the hand in patients with PD. In this double-blinded, randomized controlled trial, a convenience sample including 48 people with PD will participate based on simple non-random sampling. The participants will be allocated randomly through stratified randomization to parallel groups of intervention (sensorimotor hand rehabilitation) and control (cognitive rehabilitation) with a 1:1 allocation ratio. The associate researcher responsible for assessing outcome measures and the statistician responsible for analyzing the data are blinded to the intervention protocol. The intervention protocol for the intervention group includes hand sensory-motor rehabilitation for 10 one-and-a-half-hour sessions, 3 sessions per week, in addition to cognitive rehabilitation for 10 one-and-a-half-hour sessions, 3 sessions per week. The intervention protocol for the control group includes cognitive rehabilitation for 10 one-and-a-half-hour sessions, 3 sessions per week. All participants undergo three assessment sessions: the day before the intervention, the day after the intervention, and one month after the last intervention session. Data will be analyzed using SPSS version 22.0. The significance level will be set at 0.05.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- 23 Aug 2026
- Primary completion date
- 23 Jul 2027
- Lead sponsor
- Isfahan University of Medical Sciences
- Diseases
- Parkinson disease
- NCT number
- NCT07702929
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 23 Aug 2026 to the primary completion date, 23 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with neurological diseases other than PD
- Patients with orthopedic and internal diseases that would make participation in the study difficult
Who the study is looking for
- A diagnosis of PD by a neurologist based on the Movement Disorders Society Clinical Diagnostic Criteria for Parkinson's Disease;
- 45-65 years old: age of peak incidence of PD;
- Minimum 2 years and maximum 10 years from initial diagnosis: stabilization of the disease process and medications;
- disability level of at most 3 in the Modified Hoehn and Yahr Scale: physically independent;
- Mild cognitive impairment: score between 20 and 26 in Montreal cognitive assessment;
- Signing the written informed consent.
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Isfahan University of Medical Sciences, Isfahan, Iran Coordinator of this site? Confirm its status | Isfahan | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.